Clinical trials: Invasive Bladder Cancer
Bladder Cancer, Kidney Cancer
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
RATIONALE: Studying samples of blood and urine from patients with cancer and from healthy participants in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00900276
- Testing
- immunologic technique, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Urinary Bladder Neoplasms, Urologic Neoplasms
Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)
This study is a single-arm, open-label, single-center study to assess the safety of tislelizumab with BCG, and to obtain the preliminary efficacy results in subjects who have been diagnosed with high-risk NMIBC without prior BCG…
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Antineoplastic Agents
- Trial name
- TACBIN-01 (NCT04922047)
- Testing
- tislelizumab and BCG
- Where
- China
- Volunteers
- 6 people
- Sponsor
- RenJi Hospital
Non-Muscle-invasive Bladder Cancer (NMIBC), Bacillus Calmette-Guerin (BCG) Cystitis
Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?
Compare the different supposed clinical treatment of side effects associated with intravesical BCG by levofloxacin (quinolones) vs solifenacin (selective anti-muscarinic) vs lornoxicam (NSAID)
- Conditions
- Non-Muscle-invasive Bladder Cancer (NMIBC), Bacillus Calmette-Guerin (BCG) Cystitis, Intra-vesical Instillation
- Trial name
- NCT03038321
- Testing
- sofenacin, Tavanic, Xefo
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Mansoura University
Bladder Cancer
Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological Markers
Intravesical BCG is the mainstay adjuvant management of high risk NMIBC. Adequacy of immune system stimulation is the determinant factor for patient response to BCG.
- Trial name
- NCT04723121
- Testing
- Urine ELISA for immunological markers (IL-2 and IL-10), Reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) analysis
- Where
- Egypt
- Volunteers
- 204 people
- Sponsor
- Mansoura University
Bladder Cancer
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
To our knowledge, there are no comparative studies on bacillus Calmette-Guerin (BCG) and intravesical chemotherapy addressing quality of life (QoL) issues.
- Trial name
- NCT01697306
- Testing
- Gemcitabine 2 g, BCG Vaccine
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Bladder Cancer
Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy
The purpose of this study is to investigate the effect synchronous use of nivolumab in addition to chemoradiotherapy in patients withnon-metastatic MIBC who are not candidates for radical cystectomy
- Trial name
- NCT03993249
- Testing
- Nivolumab, chemoradiotherapy
- Where
- Greece
- Volunteers
- 78 people
- Sponsor
- Hellenic GenitoUrinary Cancer Group
Muscle-invasive Transitional Cell Carcinoma of the Bladder
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
The purpose of this study is to investigate the safety and efficacy of intratumoral REOLYSIN® therapy alone and in combination with standard neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
- Trial name
- NCT02723838
- Testing
- REOLYSIN®, Gemcitabine, Cisplatin
- Sponsor
- Oncolytics Biotech